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Will a Fixed Price Reimbursement Policy for Statins be Cost-Effective for Turkey’s Health 
Care System?  
 
Guvenc Kockaya, MD1, Albert I. Wertheimer, PhD2 
1Istanbul University, Istanbul Medicine Faculty, Pharmacology and Clinical Pharmacology Department 
2Temple University, School of Pharmacy, Center for Pharmaceutical Health Services Research 
 
The Social Security & Health section of the Turkish Statistical 
Institute (http://www.turkstat.gov.tr/) is the largest 
reimbursement foundation in Turkey covering nearly 70% of 
all health expenses for that country (www.tuik.gov.tr). In 
December 2009, the Social Security & Health foundation was 
scheduled to begin a fixed price reimbursement policy for 
several classes of medications, including the statin category, 
with the goal of reducing expenses.  However, pharmacist 
associations and pharmaceutical companies raised concerns 
about the approach because of the proposed decreases in 
reimbursement to both pharmacies and pharmaceutical 
manufacturers. In light of the concerns, the fixed price 
reimbursement policy was delayed.  
 
In the past, evaluation of statins’ cost-effectiveness has 
included assessment of the prevalence and incidence of 
diseases treated by statins [1,2], costs of morbidity and 
mortality of these diseases [1,2], relative effectiveness and 
safety of statins compared to other treatment options [1-8], 
and the relative cost-effectiveness of available statins in 
comparison to each other [2,7]. The cost-effectiveness 
evaluation conducted by Kockaya, et al. [2] was specific to 
family practice in Turkey and is particularly germane to the 
discussion in this commentary 
(http://www.scirp.org/journal/HEALTH/).   
 
The evaluations just described are extremely useful for 
decision-making, but typically are made under the 
assumptions that patients have adequate access to each 
compared medication and that the medications are used as 
directed in order to achieve outcomes similar to those 
identified through controlled clinical trials. We propose that, 
as fixed price reimbursement policies are designed and 
implemented, consideration must be given to how the 
policies would affect access to medications and patient 
adherence behaviors in light of out-of-pocket costs they may 
incur.  
 
For example, daily 10 mg rosuvastatin`s monthly treatment 
cost is nearly US$ 20 in Turkey. At the time this commentary 
was prepared, the Turkish Social Security & Health 
foundation paid approximately 80% of this amount leaving 
patient to pay only US$ 4 out-of-pocket for a one-month 
supply. However, if a fixed price reimbursement policy for 
statins is set at US$ 10 per month, this would leave US$ 10 for 
patients to pay out-of-pocket. This amount may be 
prohibitively expensive for many patients as Turkey`s 
monthly gross domestic product per capita is only US$ 750.  
 
We suggest that decisions regarding fixed price 
reimbursement policies must consider the effects of the 
policy on (1) the availability of medications (access) and (2) 
the out-of-pocket burden for patients. Such evaluations 
should include survey-based willingness-to-offer and 
willingness-to-pay analyses. Failure to consider these 
consequences of a fixed price policy could result in policies 
that decrease the amount spent on statins but increase costs 
associated with stroke, heart attack, and other cardiovascular 
diseases. Such evaluations also could help inform policy 
decisions regarding reimbursement and payment for statins 
that are used by particularly vulnerable populations. 
 
In conclusion, we propose that published cost-effectiveness 
analysis for statins can help inform decisions regarding fixed 
price policies regarding these medications. However, 
consideration must be given to how the policies would affect 
access to medications and patient adherence behaviors in 
light of out-of-pocket costs they may incur. We recommend 
that such evaluations should include survey-based 
willingness-to-offer and willingness-to-pay analyses. Failure 
to consider these consequences of a fixed price policy could 
result in policies that may decrease the amount spent on 
statins but would increase costs associated with stroke, heart 
attack, and other cardiovascular diseases. 
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